Answers are grounded in this paper and cite their sources.
A 73-year-old man was diagnosed with concurrent esophageal squamous cell carcinoma (cT3N1M0, stage IIIB) and rectal adenocarcinoma (cT2N0M0, K-ras mutation, proficient mismatch repair). Magnetic resonance imaging (MRI) revealed a 3.5-cm-long circular growth in the rectum 8.5 cm from the anus that had invaded the muscularis propria (Fig. 1). Colonoscopy revealed a 2.0-cm diameter mass located 7 cm from the anal verge, pathologically confirmed as moderately differentiated adenocarcinoma (Fig. 2). Subsequently, he received 8 cycles of chemotherapy using the FOLFOX regimen in combination with PD-1 (programmed death-1) inhibitor: sintilimab (200 mg), oxaliplatin (120 mg, 85 mg/m2), calcium folinate (600 mg, 400 mg/m2), and fluorouracil (3 g, 2.4 g/m2).
No takes yet. Share an insight, caveat, or question.
Song et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: